Guidelines for the acute respiratory viral infection treatment

A.I. Kryukov^1,2, A.B. Turovskii^1,3, I.G. Kolbanova¹, K.M. Musaev¹, A.B. Karasov¹

¹Sverzhevskiy Otorhinolaryngology Healthcare Research Institute, Moscow

²Pirogov Russian National Research Medical University, Moscow

³City Clinical Hospital named after V.V. Versaev, Moscow

Acute respiratory viral infection (ARVI) (rhinitis, sinusitis, pharyngitis, etc.) can be caused by more than 200 types of viruses, and the most common are rhinovirus, coronavirus, respiratory syncytial virus, or metapneumovirus. The virus, damaging the epithelial lining, creates the conditions for the microbial flora activation (pneumococcus, hemophilic bacillus, etc.), so that virus-bacterial associations arise. Acute respiratory infection treatment depends on the disease stage and can pursue 3 goals: causal therapy (virus control); symptomatic therapy; measures aimed at preventing and treating bacterial complications. A drug (Sialor^®) for the bacterial inflammation prevention in the nasal cavity and pharynx contains colloidal silver, which has an astringent, antiseptic and anti-inflammatory effect. Silver proteinate dissociates to form silver ions, which inhibit the bacteria growth by binding to their DNA. The anti-inflammatory action mechanism of the colloidal silver solution on the damaged mucous membrane is based on the ability to form a protective albuminate film, which reduces the mucous membrane permeability for bacteria and ensures the normal functional state of cells, contributing to the rapid restoration of the mucous membrane. All this is especially important for secondary bacterial infection prevention in acute respiratory viral infections.

Keywords: acute respiratory viral infection (ARVI), treatment, bacterial complications prevention, silver proteinate, Sialor.

For citation: Kryukov A.I., Turovskii A.B., Kolbanova I.G. et al. Guidelines for the acute respiratory viral infection treatment. RMJ. 2019;8(I):46–50.